Y Combinator · Nov 2025
Official YC launch describing Scoop’s AI agents for automating IND filings and continuous regulatory document maintenance.
Automating regulatory submissions for life sciences
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Scoop is a YC-backed, San Francisco-based AI startup building software that turns study and manufacturing data into continuously updated, submission-ready regulatory documents for life sciences teams, especially IND workflows.
Primary product
AI-native platform for drafting and continuously maintaining pre-clinical regulatory submissions (especially IND filings).
Founded
2025
Headquarters
San Francisco, California, United States
Team size
1-10
Industry
Software Development
Sub-industry
AI regulatory submission software for life sciences
Offices
0 jobs at Scoop
Check back later for new openings
Business model
Stage
seed
Total raised
$500K
Latest round
Seed · Sep 2025
Latest amount
$500K
Sep 2025 · Y Combinator
Investors
Very early-stage, two-founder YC company with a product and messaging centered on speed, regulatory rigor, traceability, and continuous updates rather than static document generation.
Compensation
No public compensation, salary, or benefits information was found.
Pricing
Sales-led / demo-based enterprise pricing; no public list price found.
Differentiators
Customers
Competitors
Y Combinator · Nov 2025
Official YC launch describing Scoop’s AI agents for automating IND filings and continuous regulatory document maintenance.
LinkedIn / Y Combinator · Nov 2025
YC’s launch post says Scoop compresses drug-trial documentation workflows from months to days and highlights the IND submission use case.
LinkedIn / Vincent Park · Nov 2025
Vincent Park announced the product publicly and said Scoop is focused on supercharging clinical trials starting with IND filings.
LinkedIn / Jay Kwon · Nov 2025
Jay Kwon described Scoop as the result of work at YC and reiterated the clinical-trials / IND submission focus.
LinkedIn / Vishal Maini · Nov 2025
A third-party launch post framed Scoop as an AI co-pilot for launching human drug trials and linked back to the YC launch.